EGFR and non-small cell lung carcinoma: The high frequency of EGFR mutations observed in AAPI individuals may also underline the higher survival rate among this population compared with other race and ethnicities (Table 1), since patients with EGFR-positive NSCLC can be treated with EGFR-targeted therapeutic products [19].